Trial Profile
ELUXA 2: An international, randomised, multi-centre, active controlled, open-label Phase III study evaluating the efficacy of BI 1482694 versus standard platinum doublet chemotherapy in patients with T790M mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on one prior epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2021
Price :
$35
*
At a glance
- Drugs Olmutinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ELUXA 2
- Sponsors Boehringer Ingelheim
- 22 Dec 2021 This trial has been completed in Belgium (Global end date: 11 Aug 2016).
- 27 Aug 2016 This trial was completed in Austria.
- 19 Aug 2016 This trial was completed in spain.